✅ 9 criteria passed
❌ 2 criteria to solve
Boost opdivo.com's SEO with Kontactr's Guest Posting.
Secure high-authority, do-follow backlinks from our trusted site—DA45 domain authority and PA55 homepage and blog pages.
Perfect for webmasters seeking higher search rankings and increased organic traffic.
Simple, quick, and effective.
opens a new window
OPDIVO® (nivolumab)
https://opdivo.com
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer. Read the indications, side effects, and more.
https://opdivo.com
OPDIVO® (nivolumab)
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer. Read the indications, side effects, and more...
No 301 redirects are in place to redirect traffic to your preferred domain. Pages that load successfully both with and without www. are treated as duplicate content! Not all versions of your page point to the same URL.
URL | Resolved URL |
http://opdivo.com | https://www.opdivo.com/ |
https://opdivo.com | SSL certificate's common name is invalid |
http://www.opdivo.com | https://www.opdivo.com/ |
https://www.opdivo.com | https://www.opdivo.com/ |
Attribute | Value |
ⓘ viewport | width=device-width, initial-scale=1 |
ⓘ The results of our semantic analysis are shown below using the website's language.
They are the main concepts covered by opdivo.com.
Each concept has a confidence score. The higher it is, the more important the topic is relative to the page.
Topics | |
Nivolumab Confidence: 91%
|
|
Prescription drug Confidence: 80%
|
|
Adverse effect Confidence: 77%
|
|
Cancer Confidence: 76%
|
|
Anticoagulant Confidence: 73%
|
✅ opdivo.com website speed is normal. Page speed is important for visitors and search engines.
Get insights to improve your page loading time.
This domain loads at the median speed of 2.8 seconds.
opdivo.com is faster than approximately 25 percent of the web. Your website page speed needs to be as fast as you can make it, without compromising the customer experience.
A good goal to achieve is a loading time of 2 seconds on desktop and mobile devices.
ⓘ This website is ranked #356.712 by Alexa.
This rank is traffic based. The lower the rank is, the better the domain is ranked.
Country | Rank |
United States of America | #94.006 |
Mobile Rendering
This website seems to be optimized for Mobile Visitors.
Phone
Tablet
A good text to HTML ratio is anywhere from 25 to 70%.
This percentage refers to the visible text ratio, as opposed to HTML elements, image tags and other non-visible information.
Great, we found headings on this page.
Top level heading |
Opdıvo® ımmunotherapy: giving people a choice and a chance against their cancer |
2nd level heading |
Patıent support resources |
5th level heading |
Select an ındication (3) |
We found 54 images on this website.
49
ALT attributes are missing on your image tags. The issue affects 33 actual different images that could be loaded more than once in your page.
Alternative text allows you to add a description to an image.
Google rely on alternative text attributes to determine relevance to a search query. Alternative text also makes an image more likely to appear in a Google image search.
It looks like you're missing alternative text for 49 images on opdivo.com. Check your website to make sure it's specified for each image on the page.
For a better readability, only the first 50 internal links are shown below.
Anchor | Type | URL |
COST AND ACCESS | text | /cost-access-affordability |
OPDIVO for people who have had prior treatments for non-small cell lung cancer | text | /advanced-nsclc |
OPDIVO for people who have had prior treatments for small cell lung cancer | text | /advanced-small-cell-lung-cancer |
OPDIVO for people with liver cancer previously treated with Nexavar® (sorafenib) | text | /advanced-hcc |
OPDIVO + YERVOY® (ipilimumab) for certain people with newly diagnosed advanced kidney cancer | text | /advanced-renal-cell-carcinoma-combination |
OPDIVO for people with previously treated advanced kidney cancer | text | /advanced-renal-cell-carcinoma |
OPDIVO + YERVOY® (ipilimumab) or OPDIVO alone for newly diagnosed advanced melanoma | text | /metastatic-melanoma |
OPDIVO for people with melanoma completely removed by surgery (adjuvant) | text | /melanoma-adjuvant-treatment |
Head and Neck Squamous Cell Cancer | text | /head-and-neck-cancer |
Advanced Liver Cancer | text | /advanced-hcc |
Advanced Bladder Cancer | text | /advanced-bladder-cancer |
Colorectal Cancer (MSI-H/dMMR) | text | /msi-h-crc |
Classical Hodgkin Lymphoma | text | /relapsed-or-progressed-chl |
Learn More | text | /patient-caregiver-support/caring-for-a-loved-one |
image | /patient-caregiver-support/patient-stories | |
WATCH VIDEOS | text | /patient-caregiver-support/patient-stories |
image | /patient-caregiver-support/patient-resources | |
FIND RESOURCES | text | /patient-caregiver-support/patient-resources |
image | /patient-caregiver-support/faqs | |
GET ANSWERS | text | /patient-caregiver-support/faqs |
1-855-OPDIVO-1 | text | tel:1-855-opdıvo-1 |
1-800-721-5072 | text | tel:18007215072 |
1-844-593-7869 | text | tel:18445937869 |
1-800-FDA-1088 | text | tel:1-800-332-1088 |
Site Map | text | /sitemap |
OPDIVO® (nivolumab) for people who have had prior treatments for non-small cell lung cancer | text | /advanced-nsclc/about-opdivo/getting-an-infusion |
OPDIVO for people who have had prior treatments for small cell lung cancer | text | /advanced-small-cell-lung-cancer/about-opdivo/getting-an-infusion |
OPDIVO + YERVOY® (ipilimumab) or OPDIVO alone for newly diagnosed advanced melanoma | text | /metastatic-melanoma/about-opdivo/getting-an-infusion/combination-therapy |
OPDIVO for people with melanoma completely removed by surgery (adjuvant) | text | /melanoma-adjuvant-treatment/about-opdivo/getting-an-infusion |
OPDIVO + YERVOY for certain people with newly diagnosed advanced kidney cancer | text | /advanced-renal-cell-carcinoma-combination/about-opdivo-yervoy/getting-an-infusion |
OPDIVO for people with previously treated advanced kidney cancer | text | /advanced-renal-cell-carcinoma/about-opdivo/getting-an-infusion |
Head and Neck Squamous Cell Cancer | text | /head-and-neck-cancer/about-opdivo/getting-an-infusion |
Advanced Liver Cancer | text | /advanced-hcc/about-opdivo/getting-an-infusion |
Advanced Bladder Cancer | text | /advanced-bladder-cancer/about-opdivo/getting-an-infusion |
Colorectal Cancer MSI-H/dMMR | text | /msi-h-crc/about-opdivo/getting-an-infusion/combination-therapy |
Classical Hodgkin Lymphoma | text | /relapsed-or-progressed-chl/about-opdivo/getting-an-infusion |
OPDIVO® (nivolumab) for people who have had prior treatments for non-small cell lung cancer | text | /advanced-nsclc/about-opdivo/clinical-trial-results |
OPDIVO for people who have had prior treatments for small cell lung cancer | text | /advanced-small-cell-lung-cancer/about-opdivo/clinical-trial-results |
OPDIVO + YERVOY® (ipilimumab) or OPDIVO alone for newly diagnosed advanced melanoma | text | /metastatic-melanoma/about-opdivo/clinical-trial-results/combination-therapy |
OPDIVO for people with melanoma completely removed by surgery (adjuvant) | text | /melanoma-adjuvant-treatment/about-opdivo/clinical-trial-results |
OPDIVO + YERVOY for certain people with newly diagnosed advanced kidney cancer | text | /advanced-renal-cell-carcinoma-combination/about-opdivo-yervoy/clinical-trial-results |
OPDIVO for people with previously treated advanced kidney cancer | text | /advanced-renal-cell-carcinoma/about-opdivo/clinical-trial-results |
Head and Neck Squamous Cell Cancer | text | /head-and-neck-cancer/about-opdivo/clinical-trial-results |
Advanced Liver Cancer | text | /advanced-hcc/about-opdivo/clinical-trial-results |
Advanced Bladder Cancer | text | /advanced-bladder-cancer/about-opdivo/clinical-trial-results |
Colorectal Cancer MSI-H/dMMR | text | /msi-h-crc/about-opdivo/clinical-trial-results/combination-therapy |
Classical Hodgkin Lymphoma | text | /relapsed-or-progressed-chl/about-opdivo/clinical-trial-results |
OPDIVO® (nivolumab) for people who have had prior treatments for non-small cell lung cancer | text | /advanced-nsclc |
OPDIVO + YERVOY for certain people with newly diagnosed advanced kidney cancer | text | /advanced-renal-cell-carcinoma-combination |
Head and Neck Squamous Cell Cancer | text | /head-and-neck-cancer |
ⓘ Domain Registrar | CSC CORPORATE DOMAINS, INC. |
ⓘ Registration Date | 11/05/2012 12 years, 14 days ago |
ⓘ Last Modified | 11/01/2019 5 years, 20 days ago |
ⓘ Expiration Date | 11/06/2020 Expired |
Host | IP Address | Country |
ns3.bms.com | 198.155.223.8 | United Kingdom |
ns4.bms.com | 158.117.22.129 | United States |
ns1.bms.com | 198.155.167.250 | United States |
ns2.bms.com | 198.155.167.248 | United States |
SOCIAL MEDIA PRESENCE
You're doing quiet good on social media!
Social shares are a key signal, among many others, that search engines use to evaluate the rankings of a website. Asking people to share your pages, adding visible social share buttons and make great quality content are 3 of the most powerful ways to grow your social presence.